Clinical Trial Update: A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating ibandronate (Bondronat) in participants with metastatic bone disease has been completed. The sponsor is Hoffmann-La Roche.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastasis
• Bone Neoplasms

Drugs mentioned

• Bondronat (ibandronic acid)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Pain; Bone Neoplasms; Neoplasm Metastasis | Phase 4 | Status: COMPLETED